HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henkel Q1

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics/Toiletries sector sales grew 19.2% to $768.9 mil. (€1=$1.29), primarily generated by the Dial, ARL and Indola acquisitions, German firm announces during a May 3 sales call. Organic sales grew .4%, the firm noted. Earnings before interest and taxes for the sector rose 34% to $88 mil., attributed mostly to the acquisitions, company adds. During the quarter, the hair/cosmetics business grew with regional launches including the colorant brand Brilliance and got2b, while the body care business "remained difficult," according to Henkel. North American revenues more than doubled during the quarter to $763.7 mil., and acquisitions grew the region's share of group revenue to 22% of total sales, versus 11% in the prior year quarter. Henkel generated net sales of $3.54 bil. in the quarter, an increase of 16.8%, and earnings before interest and taxes advanced 28.7% to $343 mil...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013029

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel